Cortellini A, et al. - In this retrospective study of advanced cancer cases continuously treated with anti-PD-1/PD-L1 inhibitors, the authors examined the association between overweight and the effectiveness of immune checkpoint inhibitors (ICIs) between September 2013 and May 2018. They noticed the primary tumors: NSCLC (65.1%), melanoma (18.7%), renal cell carcinoma (13.8%) and others (2.4%) with ECOG-PS ≥2 in 14.9% of cases. They administered PD-1/PD-L1 inhibitors as first-line treatment in 26.6% of cases. They noted that 25.2% of non-overweight cases encountered immune-related AEs (irAEs) of an unspecified grade. They noticed significantly longer median TTF, PFS, and OS for overweight/obese subjects in univariate as well as multivariate models. They pretended overweight, a tumorigenic immune-dysfunction that could definitely be reversed by ICIs. Hence, they suggested BMI as a valuable predictive tool in clinical practice.